End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity
Executive Summary
AbbVie, for the second time, has resolved a Humira patent dispute that protects the drug's US commercial exclusivity until 2023. The latest deal with Samsung Biopesis follows a similar agreement with Amgen, giving Amgen a five-month head start with its biosimilar.
You may also be interested in...
Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal
LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.
Pfizer's Essential Health Leadership On Why US Biosimilars Will Take Off – Eventually
Essential Health Group President Angela Hwang, Biosimilars President Richard Blackburn and US Biosimilars General Manager John Kennedy discuss the early challenges Pfizer has faced with Inflectra and optimism for the US biosimilars market over the long term.
Pfizer's Essential Health Leadership On Why US Biosimilars Will Take Off – Eventually
Essential Health Group President Angela Hwang, Biosimilars President Richard Blackburn and US Biosimilars General Manager John Kennedy discuss the early challenges Pfizer has faced with Inflectra and optimism for the US biosimilars market over the long term.